vs
Side-by-side financial comparison of Silvercrest Asset Management Group Inc. (SAMG) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Silvercrest Asset Management Group Inc. is the larger business by last-quarter revenue ($32.0M vs $18.6M, roughly 1.7× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -0.4%, a 66.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -0.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 2.7%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
SAMG vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.0M | $18.6M |
| Net Profit | $-120.0K | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 56.3% |
| Net Margin | -0.4% | 65.7% |
| Revenue YoY | -0.0% | 1808.5% |
| Net Profit YoY | -107.4% | 376.5% |
| EPS (diluted) | $0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.0M | $18.6M | ||
| Q3 25 | $31.3M | $334.0K | ||
| Q2 25 | $30.7M | $1.4M | ||
| Q1 25 | $31.4M | $257.0K | ||
| Q4 24 | $32.0M | $977.0K | ||
| Q3 24 | $30.4M | $660.0K | ||
| Q2 24 | $31.0M | $736.0K | ||
| Q1 24 | $30.3M | $1.4M |
| Q4 25 | $-120.0K | $12.3M | ||
| Q3 25 | $618.0K | $-8.6M | ||
| Q2 25 | $1.9M | $-6.9M | ||
| Q1 25 | $2.5M | $-5.4M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $2.3M | $-2.8M | ||
| Q2 24 | $2.7M | $-14.5M | ||
| Q1 24 | $3.0M | $411.0K |
| Q4 25 | -2.8% | 56.3% | ||
| Q3 25 | 4.3% | -2516.5% | ||
| Q2 25 | 13.2% | -701.0% | ||
| Q1 25 | 15.4% | -3350.2% | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 14.6% | -1563.6% | ||
| Q2 24 | 17.1% | -1255.0% | ||
| Q1 24 | 19.5% | -692.5% |
| Q4 25 | -0.4% | 65.7% | ||
| Q3 25 | 2.0% | -2572.2% | ||
| Q2 25 | 6.3% | -504.8% | ||
| Q1 25 | 7.9% | -2097.7% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 7.4% | -425.5% | ||
| Q2 24 | 8.6% | -1964.4% | ||
| Q1 24 | 9.9% | 29.9% |
| Q4 25 | $0.02 | $0.25 | ||
| Q3 25 | $0.07 | $-0.17 | ||
| Q2 25 | $0.21 | $-0.14 | ||
| Q1 25 | $0.26 | $-0.11 | ||
| Q4 24 | $0.16 | — | ||
| Q3 24 | $0.24 | $-0.06 | ||
| Q2 24 | $0.28 | $-0.30 | ||
| Q1 24 | $0.32 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $44.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $50.3M | $49.4M |
| Total Assets | $166.6M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $44.1M | $40.0M | ||
| Q3 25 | $36.1M | $37.9M | ||
| Q2 25 | $30.0M | $44.8M | ||
| Q1 25 | $36.3M | $40.6M | ||
| Q4 24 | $68.6M | $59.3M | ||
| Q3 24 | $58.1M | $68.8M | ||
| Q2 24 | $49.9M | $73.0M | ||
| Q1 24 | $39.7M | $80.2M |
| Q4 25 | $50.3M | $49.4M | ||
| Q3 25 | $58.9M | $36.4M | ||
| Q2 25 | $64.6M | $44.5M | ||
| Q1 25 | $80.0M | $50.5M | ||
| Q4 24 | $80.7M | $55.1M | ||
| Q3 24 | $84.6M | $58.5M | ||
| Q2 24 | $85.3M | $60.4M | ||
| Q1 24 | $83.9M | $74.1M |
| Q4 25 | $166.6M | $59.0M | ||
| Q3 25 | $157.6M | $51.1M | ||
| Q2 25 | $152.7M | $60.7M | ||
| Q1 25 | $159.9M | $67.9M | ||
| Q4 24 | $194.4M | $90.6M | ||
| Q3 24 | $184.2M | $99.0M | ||
| Q2 24 | $177.6M | $107.8M | ||
| Q1 24 | $170.2M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.6M | $18.4M |
| Free Cash FlowOCF − Capex | $15.0M | — |
| FCF MarginFCF / Revenue | 46.9% | — |
| Capex IntensityCapex / Revenue | 11.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $17.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.6M | $18.4M | ||
| Q3 25 | $14.6M | $-8.7M | ||
| Q2 25 | $13.8M | $-7.5M | ||
| Q1 25 | $-24.7M | $-7.5M | ||
| Q4 24 | $21.6M | $-24.0M | ||
| Q3 24 | $13.3M | $765.0K | ||
| Q2 24 | $16.0M | $-10.9M | ||
| Q1 24 | $-24.1M | $-4.0M |
| Q4 25 | $15.0M | — | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $13.4M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $19.9M | — | ||
| Q3 24 | $12.9M | — | ||
| Q2 24 | $15.6M | — | ||
| Q1 24 | $-24.7M | — |
| Q4 25 | 46.9% | — | ||
| Q3 25 | 44.1% | — | ||
| Q2 25 | 43.6% | — | ||
| Q1 25 | -80.0% | — | ||
| Q4 24 | 62.2% | — | ||
| Q3 24 | 42.4% | — | ||
| Q2 24 | 50.4% | — | ||
| Q1 24 | -81.6% | — |
| Q4 25 | 11.4% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 23.62× | — | ||
| Q2 25 | 7.22× | — | ||
| Q1 25 | -10.01× | — | ||
| Q4 24 | 13.34× | — | ||
| Q3 24 | 5.90× | — | ||
| Q2 24 | 6.00× | — | ||
| Q1 24 | -8.03× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
